Drug intelligence / Profile preview

buprenorphine + codeine + tramadol

Development stage
Unknown
Lead developer
Reckitt
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

This is a combination of three opioid analgesics—buprenorphine, codeine, and tramadol. Each component acts on the central nervous system to relieve pain but through slightly different mechanisms: - Buprenorphine is a partial agonist at the mu-opioid receptor with high affinity but limited intrinsic activity, providing analgesia with a ceiling effect for respiratory depression. It also acts as an antagonist at kappa-opioid receptors. - Codeine is a prodrug that requires metabolic activation (primarily via CYP2D6) to morphine, which then acts as an agonist at mu-opioid receptors to provide analgesia. - Tramadol is both a weak mu-opioid receptor agonist and an inhibitor of serotonin and norepinephrine reuptake (SNRI), contributing to its multimodal pain-relieving effects. The combination would theoretically provide additive or synergistic analgesic effects due to their complementary mechanisms. However, combining multiple opioids increases the risk of adverse effects such as respiratory depression, sedation, serotonin syndrome (especially due’s SNRI activity), dependence, abuse potential, and overdose. There are no known approved pharmaceutical products containing all three agents together; such combinations are generally not recommended in clinical practice due to safety concerns[1][3][4][5].

Other names
buprenorphine and codeine and tramadolbuprenorphine/codeine/tramadol
02

Targets

NET (Norepinephrine Transporter)KOR (Kappa opioid receptor)SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on buprenorphine + codeine + tramadol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on buprenorphine + codeine + tramadol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call